ABI
VRTX icon

Adamant Biomedical Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Adamant Biomedical Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$8.67M Hold
73,000
– – 2.07% 11
2014
Q3 		$8.2M Buy
+73,000
New +$6.95M 2.05% 13

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adamant Biomedical Investments's VRTX Position: Q4 2014 in Review

Adamant Biomedical Investments held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2014 at 73,000 shares worth $8.67M. The position accounts for 2.07% of the portfolio, ranked #11.

Adamant Biomedical Investments first reported a position in VRTX in Q3 2014 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

  • Adamant Biomedical Investments held 73,000 shares of Vertex Pharmaceuticals worth $8.67M as of Q4 2014.
  • Adamant Biomedical Investments left its Vertex Pharmaceuticals share count unchanged in Q4 2014.
  • Vertex Pharmaceuticals made up 2.07% of Adamant Biomedical Investments's portfolio in Q4 2014, its #11 holding.
  • Adamant Biomedical Investments first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.